This suggests that it is possible to analyze maternal peripheral blood to predict the severity of postnatal SMA in the child and that induction of maternal SMN expression might be an effective therapeutic strategy for the fetus. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.